The Relationship between Acute Coronary Syndrome and Stress Hyperglycemia

Abstract

Background and Objective:

Hyperglycemia on admission is associated with increased mortality and morbidity in acute coronary syndrome (ACS) irrespective of presence of diabetes mellitus. To the best of our knowledge, no evidence on the relationship between stress hyperglycemia (SH) and the extent of coronary artery disease is found in the literature. Our objective in this study is to assess the relationship of SH with the prognosis of acute coronary syndrome, extent of coronary artery disease (CAD), development of arrhythmia, and major adverse cardiac events.

Method:

89 patients who were hospitalized in the coronary intensive care unit with diagnosis of ACS between January 2010 and June 2010 were enrolled in the study. The patients were separated into 2 groups as having stress hypergly­cemia or not, according to their blood glucose levels on admission. TIMI and GRACE risk scores were obtained and GENSINI scoring was performed to assess CAD extent for all the patients. Major adverse cardiac events (MACE) (death, MI, re-revascularization, stroke) were recorded for all patients while in the hospital and at 1^st and 6^th months.

Results:

In our study, MACE, GENSINI scores at 6 months and development of in-hospital arrhythmia rates were statistically significantly higher and left ventricular ejection fractions were statistically significantly lower in the group with SH. The association of TIMI, GRACE, GENSINI, New York Heart Association (NYHA) and Killip classifications with blood glucose, fasting blood glucose and HbA1c on admission was confirmed.

Conclusion:

Prognostic course happens to be worse and CAD is more extensive in patients with SH. In addition, blood glucose values may have to be estimated lower compared to the samples in the literature, in order to diagnose SH.

Key words

acute coronary syndromes - stress hyperglycemia - extent of coronary artery disease

• References

• 1 McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17: 107-124
• 2 Katz LE, DeLeon DD, Zhao H et al. Free and total insulin-like growth factor (IGF)-I levels decline during fasting: relationships with insulin and IGF-binding protein-1. J Clin Endocrinol Metab 2002; 87: 2978-2983
• 3 Bolk J, van der Ploeg T, Cornel JH et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001. 79. 207-214
• 4 Kosiborod M, Rathore SS, Inzucchi SE et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005; 111: 3078-3086
• 5 Capes SE, Hunt D, Malmberg K et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-778
• 6 Ertorer ME, Haydardedeoglu FE, Erol T et al. Newly diagnosed hyperglycemia and stress hyperglycemia in a coronary intensive care unit. Diabetes Res Clin Pract 2010; 90: 8-14
• 7 Ceriello A. Acute hyperglycaemia: a ‘new’ risk factor during myocardial infarction. Eur Heart J 2005; 26: 328-331
• 8 Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006; 29: 765-770
• 9 Malmberg K, Norhammar A, Wedel H et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99: 2626-2632
• 10 Mellbin LG, Malmberg K, Norhammar A et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008; 29: 166-176
• 11 Diaz R, Goyal A, Mehta SR et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007; 298: 2399-2405
• 12 G.G G editor Coronary arteriography. 1975 ed. NY, 261. Futura publishing Co.; 1975
• 13 Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-2144
• 14 Rouleau JL, Packer M, Moye L et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-591
• 15 Nian M, Lee P, Khaper N et al. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004; 94: 1543-1553
• 16 Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon. J Clin Invest 1979; 63: 485-493
• 17 Ceriello A, Giugliano D, Quatraro A et al. Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism 1989; 38: 1162-1163
• 18 Ceriello A, Giugliano D, Quatraro A et al. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988; 31: 889-891
• 19 Giugliano D, Marfella R, Coppola L et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-1790
• 20 Williams SB, Goldfine AB, Timimi FK et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-1701
• 21 Marfella R, Di Filippo C, Portoghese M et al. Tight glycemic control reduces heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients. J Am Coll Cardiol 2009; 53: 1425-1436
• 22 Dandona P, Aljada A, Chaudhuri A et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454
• 23 Garadah TS, Kassab S, Al-Shboul QM et al. The threshold of admission glycemia as a predictor of adverse events in diabetic and non-diabetic patients with acute coronary syndrome. Clin Med Cardiol 2009; 3: 29-36
• 24 de Mulder M, Oemrawsingh RM, Stam F et al. Current management of hyperglycemia in acute coronary syndromes: a national Dutch survey. Crit Pathw Cardiol 2009; 8: 66-70 quiz 1
• 25 Kociol RD, Peterson ED, Hammill BG et al. National survey of hospital strategies to reduce heart failure readmissions: findings from the Get With the Guidelines-Heart Failure registry. Circ Heart Fail 2012; 5: 680-687
• 26 de Mulder M, Umans VA, Stam F et al. Intensive management of hyperglycaemia in acute coronary syndromes. Study design and rationale of the BIOMArCS 2 glucose trial. Diabet Med 2011; 28: 1168-1175
• 27 Iwakura K, Ito H, Ikushima M et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003; 41: 1-7
• 28 Kosiborod M, Inzucchi SE, Krumholz HM et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008; 117: 1018-1027
• 29 Pinto DS, Skolnick AH, Kirtane AJ et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2005; 46: 178-180